Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 346

1.

sRANKL and OPG in serum and synovial fluid of patients with rheumatoid arthritis in comparison to non-destructive chronic arthritis.

Hein GE, Meister M, Oelzner P, Franke S.

Rheumatol Int. 2008 Jun;28(8):765-9. doi: 10.1007/s00296-007-0514-3. Epub 2008 Jan 3.

PMID:
18172654
[PubMed - indexed for MEDLINE]
2.

Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis.

Skoumal M, Kolarz G, Haberhauer G, Woloszczuk W, Hawa G, Klingler A.

Rheumatol Int. 2005 Nov;26(1):63-9. Epub 2005 May 12.

PMID:
15889303
[PubMed - indexed for MEDLINE]
3.

Synovial fluid RANKL and matrix metalloproteinase levels in enthesitis related arthritis subtype of juvenile idiopathic arthritis.

Agarwal S, Misra R, Aggarwal A.

Rheumatol Int. 2009 Jun;29(8):907-11. doi: 10.1007/s00296-008-0805-3. Epub 2008 Dec 4.

PMID:
19052752
[PubMed - indexed for MEDLINE]
4.

High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment.

Ziolkowska M, Kurowska M, Radzikowska A, Luszczykiewicz G, Wiland P, Dziewczopolski W, Filipowicz-Sosnowska A, Pazdur J, Szechinski J, Kowalczewski J, Rell-Bakalarska M, Maslinski W.

Arthritis Rheum. 2002 Jul;46(7):1744-53.

PMID:
12124857
[PubMed - indexed for MEDLINE]
Free Article
5.

Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis - relationship with bone mineral density, disease activity and bone turnover.

Oelzner P, Franke S, Lehmann G, Eidner T, Müller A, Wolf G, Hein G.

Clin Rheumatol. 2007 Dec;26(12):2127-35. Epub 2007 May 31.

PMID:
17541498
[PubMed - indexed for MEDLINE]
6.

The imbalance between osteoprotegerin and cathepsin K in the serum of patients with longstanding rheumatoid arthritis.

Skoumal M, Haberhauer G, Kolarz G, Hawa G, Woloszczuk W, Klingler A, Varga F, Klaushofer K.

Rheumatol Int. 2008 May;28(7):637-41. Epub 2007 Dec 13.

PMID:
18075741
[PubMed - indexed for MEDLINE]
7.

Ferritin correlates with C-reactive protein and acute phase serum amyloid A in synovial fluid, but not in serum.

Kumon Y, Suehiro T, Nishiya K, Hashimoto K, Nakatani K, Sipe JD.

Amyloid. 1999 Jun;6(2):130-5.

PMID:
10439120
[PubMed - indexed for MEDLINE]
8.

High levels of synovial fluid osteoprotegerin (OPG) and increased serum ratio of receptor activator of nuclear factor-kappa B ligand (RANKL) to OPG correlate with disease severity in patients with primary knee osteoarthritis.

Pilichou A, Papassotiriou I, Michalakakou K, Fessatou S, Fandridis E, Papachristou G, Terpos E.

Clin Biochem. 2008 Jun;41(9):746-9. doi: 10.1016/j.clinbiochem.2008.02.011. Epub 2008 Mar 8.

PMID:
18355453
[PubMed - indexed for MEDLINE]
9.

Circulating osteoprotegerin and soluble RANK ligand in systemic sclerosis.

Dovio A, Data V, Carignola R, Calzolari G, Vitetta R, Ventura M, Saba L, Severino A, Angeli A.

J Rheumatol. 2008 Nov;35(11):2206-13. Epub 2008 Oct 1.

PMID:
18843778
[PubMed - indexed for MEDLINE]
10.

sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients.

Doumouchtsis KK, Kostakis AI, Doumouchtsis SK, Tziamalis MP, Tsigris C, Kostaki MA, Perrea DN.

J Endocrinol Invest. 2007 Oct;30(9):762-6.

PMID:
17993768
[PubMed - indexed for MEDLINE]
11.

Soluble receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation.

Chen CH, Chen HA, Liao HT, Liu CH, Tsai CY, Chou CT.

Clin Rheumatol. 2010 Oct;29(10):1155-61. doi: 10.1007/s10067-010-1543-y. Epub 2010 Aug 6.

PMID:
20690034
[PubMed - indexed for MEDLINE]
12.

Matrix metalloproteinases MMP-3 and MMP-1 levels in sera and synovial fluids in patients with rheumatoid arthritis and osteoarthritis.

Mahmoud RK, El-Ansary AK, El-Eishi HH, Kamal HM, El-Saeed NH.

Ital J Biochem. 2005 Sep-Dec;54(3-4):248-57.

PMID:
16688934
[PubMed - indexed for MEDLINE]
13.

Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor-kappa B ligand, and high-sensitivity C-reactive protein in patients with active rheumatoid arthritis randomized to etanercept alone or in combination with methotrexate.

Sennels H, Sørensen S, Ostergaard M, Knudsen L, Hansen M, Skjødt H, Peters N, Colic A, Grau K, Jacobsen S.

Scand J Rheumatol. 2008 Jul-Aug;37(4):241-7. doi: 10.1080/03009740801910320.

PMID:
18612923
[PubMed - indexed for MEDLINE]
14.

Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.

Doumouchtsis K, Perrea D, Doumouchtsis S, Tziamalis M, Poulakou M, Vlachos I, Kostakis A.

Ther Apher Dial. 2009 Feb;13(1):49-55. doi: 10.1111/j.1744-9987.2009.00653.x.

PMID:
19379170
[PubMed - indexed for MEDLINE]
15.

Gingival crevicular fluid, serum levels of receptor activator of nuclear factor-κB ligand, osteoprotegerin, and interleukin-17 in patients with rheumatoid arthritis and osteoporosis and with periodontal disease.

Gümüş P, Buduneli E, Bıyıkoğlu B, Aksu K, Saraç F, Nile C, Lappin D, Buduneli N.

J Periodontol. 2013 Nov;84(11):1627-37. doi: 10.1902/jop.2013.120595. Epub 2013 Jan 17.

PMID:
23327689
[PubMed - indexed for MEDLINE]
16.

Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis.

Feuerherm AJ, Borset M, Seidel C, Sundan A, Leistad L, Ostensen M, Faxvaag A.

Scand J Rheumatol. 2001;30(4):229-34.

PMID:
11578019
[PubMed - indexed for MEDLINE]
17.

Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies.

Usón J, Balsa A, Pascual-Salcedo D, Cabezas JA, Gonzalez-Tarrio JM, Martín-Mola E, Fontan G.

J Rheumatol. 1997 Nov;24(11):2069-75.

PMID:
9375862
[PubMed - indexed for MEDLINE]
18.

Reduction of urinary levels of pyridinoline and deoxypyridinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheumatoid arthritis.

Yasunori K, Masaaki T, Tetsuyuki N, Hayato K, Akira N.

Clin Rheumatol. 2008 Sep;27(9):1093-101. doi: 10.1007/s10067-008-0870-8. Epub 2008 Mar 13.

PMID:
18338203
[PubMed - indexed for MEDLINE]
19.

Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.

Chiba Y, Onouchi T, Ikeda T, Adachi J, Tamura Y, Horiuchi T.

Gerontology. 2009;55(3):275-80. doi: 10.1159/000196280. Epub 2009 Jan 22.

PMID:
19158438
[PubMed - indexed for MEDLINE]
20.

Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis.

Kane D, Roth J, Frosch M, Vogl T, Bresnihan B, FitzGerald O.

Arthritis Rheum. 2003 Jun;48(6):1676-85.

PMID:
12794836
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk